CD274 and graft versus host disease: Furthermore, JES6 treatment capitalizes on variations in PD-L1 expression between GVHD target tissues and lymphoid tissues to selectively maintain GVL activity within lymphohematopoietic compartments while simultaneously preventing GVHD in parenchymal tissues.